HOVON 116 trial: Epigenetic therapy with panobinostat and/or decitabine after allo-SCT for poor-risk AML

Allogeneic stem cell transplantation (allo-SCT) is the current standard of care for patients with poor-risk acute myeloid leukemia (AML).¹ Allo-SCT aims at establishing remission by exploiting the graft-versus-leukemia (GvL) effect. Nevertheless, especially in poor-risk patients, disease relapse following allo-SCT is still one of the main reasons of failure in AML.¹ Thus, there is a great need for treatments that enhance the GvL effect when combined with allo-SCT, to lead to better outcomes. For this reason, Burak Kalin et al.¹ investigated in the phase I/II trial, HOVON 116, the feasibility and preliminary efficacy of epigenetic therapy with panobinostat (PNB) and/or decitabine (DAC) in poor-risk AML patients. The results of this study were published in Blood Advances and are summarized below.

Study design

• Prospective, multicenter, phase I/II feasibility trial
• The study included poor and very poor-risk patients, aged 18–70, with AML or refractory anemia with excess blasts, prior to the start of the second induction chemotherapy cycle. The treatment intention for responding patients was to receive allo-SCT 6–8 weeks after the second induction chemotherapy cycle
• In the phase I part of the study, three dosing schedules were explored in 29 very-poor-risk patients with AML:
  • Dose 1 (PNB): 20 mg panobinostat at Days 1, 4, 8, and 11, of 4-week cycles
  • Dose 2 (PNB/DAC20): 20 mg panobinostat monotherapy at Days 1, 4, 8, and 11 in combination with 20 mg/m² decitabine at Days 1–3, of 4-week cycles
  • Dose 3 (PNB/DAC10): 20 mg panobinostat monotherapy at Days 1, 4, 8, and 11 in combination with 10 mg/m² decitabine at Days 1–3, of 4-week cycles
• The primary endpoint of phase I was the feasibility of these three dosing schedules based on their dose-limiting toxicities (DLTs) in the first treatment cycle
• In the phase II part, only the most feasible, PNB and PNB/DAC10 dosages were further assessed, primarily for their safety, and secondarily for their efficacy
• The treatment scheme of the study is shown below in Figure 1

 Figure 1. Study scheme for HOVON 116¹ 
AML, acute myeloid leukemia; allo-SCT, allogeneic stem cell transplantation; DAC, decitabine; DLI, donor lymphocyte infusion; GvHD, graft-versus-host disease; PNB, panobinostat; RAEB, refractory anemia with excess blasts; RIC, reduced-intensity conditioning.

Results

A total of 110 patients who were registered in the study underwent allo-SCT. The key patient baseline characteristics are shown below in Table 1. Briefly, the median age was 59 years, the majority of patients had a World Health Organization (WHO) performance status of 0–1 (83%) and a very poor HOVON/SAKK risk classification (70%)

Table 1. Patient baseline characteristics in HOVON 116¹

Phase I part

• DLTs were experienced by:
  • 1/9 patients in the PNB group
  • 1/10 patients in the PNB/DAC10 group
  • 4/10 patients in the PNB/DAC20 group
• Due to the high proportion of prolonged cytopenia DLTs observed in the PNB/DAC20 group, this was not further evaluated in the phase II part of the study

Phase II part

• Of the 110 patients who underwent allo-SCT, 87 received their first treatment cycle with either PNB or PNB/DAC10
• In total, 55% of patients were eligible for donor lymphocyte infusion (DLI) within 115 days, and 84% of patients who received a second PNB or PNB/DAC10 cycle received their first DLI
• Second and third DLIs were successfully given to 40 and 25 patients, respectively
• The main reasons for PNB or PNB/DAC10 withdrawal were:
  • Graft-versus-host disease (GvHD; n = 11)
  • Thrombocytopenia (n = 3)
  • Renal dysfunction (n = 3)
  • Death (n = 2)
  • Disease progression (n = 2)
  • Liver dysfunction (n = 1)
  • Start of Cycle 1 after Day 35 post allo-SCT (n = 1)
• Treatment-related adverse events (TEAEs) by system are shown below in Table 2. Grade 3–4 adverse events (AEs) due to PNB/DAC treatment were seen in 26% of patients
• In general, TEAEs were easily manageable with quick recovery following treatment discontinuation

Table 2. Treatment-related toxicities by system in the HOVON 116¹

• With regard to preliminary efficacy results, these are shown in Table 3, and these account for all patients who underwent allo-SCT. When looking at the different dosing schedules, there was no difference in the 2-year cumulative relapse incidence between the PNB (24%) and PNB/DAC10 groups (46%; p = 0.29)
• When stratifying patients by HOVON risk, very poor-risk patients with AML had a lower 2-year OS rate than those with poor-risk AML (46% vs 63%)
• In the total cohort, Grade 3–4 and Grade 2–4 acute GvHD rates at 6 months were 5% and 23%, respectively. At 12 months, moderate-to-severe chronic GvHD had developed in 22% of patients
• None of the patients required systemic GvHD therapy or experienced relapse at the time of follow-up

Table 3. Efficacy outcomes from HOVON 116¹

Conclusion

 The results of this phase I/II trial showed that panobinostat monotherapy or in combination with 10 mg/m² decitabine are feasible and tolerable epigenetic regimens for patients with poor-risk AML, who have undergone allo-SCT. Data did not indicate a synergistic or additive effect of panobinostat and decitabine. Due to the preliminary nature of these results, further large-scale prospective trials are needed to assess the efficacy of these post allo-SCT epigenetic therapies for the treatment of AML patients with poor outcomes.